Stevanato Group reports Q3 adjusted EPS EUR0.14 vs. EUR0.12 last year

Reports Q3 revenue EUR303.2M vs. EUR277.9M last year. CEO Franco Stevanato stated, “We delivered a solid Q3 with 9% revenue growth and a record 47% increase in high-value solutions, driven primarily by demand for high-performance Nexa syringes. Financial results were better-than-expected due to the timing of product shipments that were previously expected to occur in Q4, and we remain on track to achieve our FY25 guidance. Our strategic investments in capacity expansion and innovation position us to meet rising demand for injectable biologics, biosimilars, and ready-to-use platforms, to support our customers with patient-centric solutions.”